Studies for Women with HIV

• Anti-Lipolytic Strategy for HIV Lipodystrophy
  The study will evaluate the use of acipimox, a drug that blocks the breakdown of fat and is used to treat high cholesterol. People with HIV lipodystrophy (fat redistribution) may have high blood levels of cholesterol and triglyceride (small particles of fat in the blood). We are evaluating whether acipimox will reduce triglyceride levels in individuals with HIV lipodystrophy.

For more information, please contact Jim Liebau, NP at (617) 724-6926.

• Effects of a Lifestyle Modification Program (REACH) in Patients with HIV and Metabolic Syndrome
  This study will determine the effects of an intensive lifestyle modification program, focusing on healthy eating and exercise, in patients with HIV and Metabolic Syndrome. Metabolic Syndrome is a cluster of characteristics such as high blood pressure, high cholesterol, large waist circumference, and insulin resistance. We hope to improve body composition, blood pressure, cholesterol levels, and other factors including quality of life. Patients will be randomly selected for one-on-one sessions with a nutritionist over six months.

For more information, please contact Kathleen Fitch, NP at (617) 724-8015.

• Long-term Physiologic Effects of GH in HIV Lipodystrophy
  HIV positive subjects age 18-65 with changes in body fat distribution are needed for a three-year research study investigating treatment with growth hormone. Participants will self-inject growth hormone for 18 months and placebo (contains no active ingredients) for 18 months. Participation in this study requires an initial screen visit, and, if you qualify, 17 outpatient visits over 3 years. Compensation up to $500 is provided.

For more information, please contact Dr. Polyxeni Koutkia at (617) 726-8277.

• Mechanisms and Clinical Effects of Adrenal Androgen Shunting in HIV Disease
  HIV positive women age 18-45 with weight loss are needed for a 16-day research study using a research drug to treat low level testosterone levels (androgen deficiency). Participants will take metyrapone (a research drug) or placebo (an inactive pill) for 14 days. Participation in this study requires an initial screen visit, and, if you qualify, a baseline in-patient visit during the first four days, daily outpatient visits for the next ten days, and a final overnight visit from day 15-16. Compensation up to $500 is provided.

For more information, please contact Dr. Polyxeni Koutkia at (617) 726-8277.